Files
Document type
ArticleVersion
Published versionPublication date
Publication license
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/133456
Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects
Journal Title
Director/Tutor
Journal ISSN
Volume Title
Related resource
Abstract
Recently, the use of nebulized antibiotics in the intensive care unit, in particular amikacin, has been the subject of much discussion, owing to unconvincing results from the latest randomized clinical trials. Here, we examine and reappraise the evidence in favor and against this therapeutic strategy; we then discuss the potential factors that might have played a role in the negative findings of recent clinical trials. Also, we call attention to several factors that are seldom considered by study developers and regulatory agencies, to promote translational research in this field and improve the design of future randomized clinical trials.
Subject (English)
Citation
Citation
TORRES MARTÍ, Antoni, et al. Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects. Critical Care. 2018. Vol. 22, num. 1, pags. 343. ISSN 1364-8535. [consulted: 13 of August of 2026]. Available at: https://hdl.handle.net/2445/133456